Neuroimaging as a potential biomarker to optimize psychiatric research and treatment

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Esther Walton - , Klinik und Poliklinik für Kinder- und Jugendmedizin (Autor:in)
  • Jessica A. Turner - , The Mind Research Network, University of New Mexico (Autor:in)
  • Stefan Ehrlich - , Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Universitätsklinikum Carl Gustav Carus Dresden, Massachusetts General Hospital, Harvard Medical School (HMS), Athinoula A. Martinos Center for Biomedical Imaging (Autor:in)

Abstract

Complex, polygenic phenotypes in psychiatry hamper our understanding of the underlying molecular pathways and mechanisms of many diseases. The unknown aetiology, together with symptoms which often show a large variability both across individuals and over time and also tend to respond comparatively slowly to medication, can be a problem for patient treatment and drug development. We argue that neuroimaging has the potential to improve psychiatric treatment in two ways. First, by reducing phenotypic complexity, neuroimaging intermediate phenotypes can help to identify disease-related genes and can shed light into the biological mechanisms of known risk genes. Second, quantitative neuroimaging markers-reflecting the spectrum of impairment on a brain-based level-can be used as a more sensitive, reliable and immediate treatment response biomarker. In the end, enhancing both our understanding of the pathophysiology of psychiatric disorders and the prediction of treatment success could eventually optimise current therapy plans.

Details

OriginalspracheEnglisch
Seiten (von - bis)619-631
Seitenumfang13
FachzeitschriftInternational Review of Psychiatry
Jahrgang25
Ausgabenummer5
PublikationsstatusVeröffentlicht - 2013
Peer-Review-StatusJa

Externe IDs

PubMed 24151806
ORCID /0000-0003-2132-4445/work/160950903

Schlagworte

Ziele für nachhaltige Entwicklung